This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kulke, M. H. Articles by Fuchs, C. S. Search for Related Content PubMed Articles by Kulke, M. H. Articles by Fuchs, C. S. Social Bookmarking                            What's this?

Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors

From the Department of Medical Oncology, Dana-Farber Cancer Institute; Division of Hematology/Oncology, Beth Israel-Deaconess Medical Center; Division of Hematology/Oncology, and Department of Biostatistics, Massachusetts General Hospital; and Channing Laboratory, Brigham and Women’s Hospital, Boston, MA

Address reprint requests to Matthew H. Kulke, MD, Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115; e-mail: matthew_kulke{at}dfci.harvard.edu

Purpose Standard, intravenous chemotherapy regimens for neuroendocrine tumors have been associated with limited response rates and significant toxicity. We evaluated the efficacy of an oral regimen of temozolomide and thalidomide in patients with metastatic carcinoid, pheochromocytoma, or pancreatic neuroendocrine tumors.

Patients and Methods Twenty-nine patients were treated with a combination of temozolomide, administered at a dose of 150 mg/m² for 7 days, every other week, and thalidomide at doses of 50 to 400 mg daily. Patients were followed for evidence of toxicity, biochemical response, radiologic response, and survival.

Results Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors). The median duration of response was 13.5 months, 1-year survival was 79%, and 2-year survival was 61%. The median administered dose of temozolomide was 150 mg/m², and the median administered dose of thalidomide was 100 mg daily. Grade 3-4 toxicities were uncommon, with the exception of grade 3-4 lymphopenia, which developed in 69% of the patient population. Opportunistic infections occurred in three patients (10%) during the time of lymphopenia, and included single cases of Pneumocystis carinii pneumonia, disseminated varicella zoster virus, and herpes simplex virus.

Conclusion Orally administered temozolomide and thalidomide seems to be an active regimen for the treatment of neuroendocrine tumors. In this 29-patient study, this regimen appeared more active in pancreatic endocrine tumors than in carcinoid tumors.

Supported by Schering-Plough and Celgene, in part by NIH Grants No. K23 CA 093401, K30 HL04095 (M.H.K.), and gifts from Dr Raymond and Beverly Sackler, the Caring for Carcinoid Foundation, and the Stephen and Caroline Kaufer Fund for Neuroendocrine Tumor Research.

Presented in part at the 2003 Chemotherapy Foundation Symposium, New York, NY, November 12-15, 2003.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Rinke, H.-H. Muller, C. Schade-Brittinger, K.-J. Klose, P. Barth, M. Wied, C. Mayer, B. Aminossadati, U.-F. Pape, M. Blaker, et al. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group J. Clin. Oncol., October 1, 2009; 27(28): 4656 - 4663. [Abstract] [Full Text] [PDF]

				K.-S. Park, J.-L. Lee, H. Ahn, J.-M. Koh, I. Park, J.-S. Choi, Y. R. Kim, T. S. Park, J.-H. Ahn, D. H. Lee, et al. Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma Jpn. J. Clin. Oncol., May 1, 2009; 39(5): 327 - 331. [Abstract] [Full Text] [PDF]

				C. Jimenez, M. E. Cabanillas, L. Santarpia, E. Jonasch, K. L. Kyle, E. A. Lano, S. F. Matin, R. F. Nunez, N. D. Perrier, A. Phan, et al. Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 386 - 391. [Abstract] [Full Text] [PDF]

				A. M. Joshua, S. Ezzat, S. L. Asa, A. Evans, R. Broom, M. Freeman, and J. J. Knox Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma J. Clin. Endocrinol. Metab., January 1, 2009; 94(1): 5 - 9. [Abstract] [Full Text] [PDF]

				M. H. Kulke, J. L. Hornick, C. Frauenhoffer, S. Hooshmand, D. P. Ryan, P. C. Enzinger, J. A. Meyerhardt, J. W. Clark, K. Stuart, C. S. Fuchs, et al. O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors Clin. Cancer Res., January 1, 2009; 15(1): 338 - 345. [Abstract] [Full Text] [PDF]

				L. K. Kvols Revisiting C.G. Moertel's Land of Small Tumors J. Clin. Oncol., November 1, 2008; 26(31): 5005 - 5007. [Full Text] [PDF]

				J. C. Yao, A. T. Phan, D. Z. Chang, R. A. Wolff, K. Hess, S. Gupta, C. Jacobs, J. E. Mares, A. N. Landgraf, A. Rashid, et al. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study J. Clin. Oncol., September 10, 2008; 26(26): 4311 - 4318. [Abstract] [Full Text] [PDF]

				M. H. Kulke, H.-J. Lenz, N. J. Meropol, J. Posey, D. P. Ryan, J. Picus, E. Bergsland, K. Stuart, L. Tye, X. Huang, et al. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., July 10, 2008; 26(20): 3403 - 3410. [Abstract] [Full Text] [PDF]

				J. T. Adler, G. Y. Meyer-Rochow, H. Chen, D. E. Benn, B. G. Robinson, R. S. Sippel, and S. B. Sidhu Pheochromocytoma: Current Approaches and Future Directions Oncologist, July 1, 2008; 13(7): 779 - 793. [Abstract] [Full Text] [PDF]

				B. Vahid and P. E. Marik Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors* Chest, February 1, 2008; 133(2): 528 - 538. [Abstract] [Full Text] [PDF]

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]

				L. P. Girard and D. B. Gregson Community-Acquired Lung Abscess Caused by Legionella micdadei in a Myeloma Patient Receiving Thalidomide Treatment J. Clin. Microbiol., September 1, 2007; 45(9): 3135 - 3137. [Abstract] [Full Text] [PDF]

				K.-C. Chen, Y.-L. Chang, C.-T. Pan, and Y.-C. Lee Esophageal atypical carcinoid tumor with tracheal invasion J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 524 - 525. [Full Text] [PDF]

				I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero New drug development in digestive neuroendocrine tumors Ann. Onc., August 1, 2007; 18(8): 1307 - 1313. [Abstract] [Full Text] [PDF]

				M. H Kulke Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr. Relat. Cancer, June 1, 2007; 14(2): 207 - 219. [Abstract] [Full Text] [PDF]

				E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232. [Abstract] [Full Text] [PDF]

				S. Ekeblad, A. Sundin, E. T. Janson, S. Welin, D. Granberg, H. Kindmark, K. Dunder, G. Kozlovacki, H. Orlefors, M. Sigurd, et al. Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors Clin. Cancer Res., May 15, 2007; 13(10): 2986 - 2991. [Abstract] [Full Text] [PDF]

				T. Scholz, G. Eisenhofer, K. Pacak, H. Dralle, and H. Lehnert Current Treatment of Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1217 - 1225. [Abstract] [Full Text] [PDF]

				B. H. Kushner, K. Kramer, S. Modak, and N.-K. V. Cheung Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma J. Clin. Oncol., November 20, 2006; 24(33): 5271 - 5276. [Abstract] [Full Text] [PDF]

				M. H. Kulke, E. K. Bergsland, D. P. Ryan, P. C. Enzinger, T. J. Lynch, A. X. Zhu, J. A. Meyerhardt, J. V. Heymach, W. E. Fogler, C. Sidor, et al. Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors J. Clin. Oncol., August 1, 2006; 24(22): 3555 - 3561. [Abstract] [Full Text] [PDF]